Abstract:Lu Xie Jie Xu Sen Dong Jian Gao Xiaodong Tang Taiqiang Yan Rongli Yang Wei Guo 1Musculoskeletal Tumor Center, Peking University People’s Hospital, Beijing, People’s Republic of China; 2Catheterization Room & Radiology Department, Peking University People’s Hospital, Beijing, People’s Republic of China Purpose: We intend to analyze the gain and loss from transcatheter intra-arterial (IA) limb infusion of cisplatin for extremity osteosarcoma in the past six years. Patients and methods: Between December 2009 and August 2014, a total of 99 patients were analyzed for efficiency and followed up for long-term survival. Based on the different administration methods of cisplatin, we divided them into the following two cohorts: IA infusion of cisplatin (n=48) and intravenous (IV) infusion of cisplatin (n=51). Except for cisplatin, all the other drugs were given intravenously. Cisplatin was given intra-arterially with an infusion time of 3 hrs or 6 hrs using a pump, whereas historical controls received IV infusion of cisplatin within 60 mins. Tumor neovascularity (TNV) was analyzed before infusion, and subsequent arteriograms were compared with the baseline to determine percent changes. Definitive surgery with intended wide resection and postoperative pathological evaluation were performed in all these patients. Results: No local or overall survival benefit was found in the patients preoperatively treated with IA infusion of cisplatin compared with IV infusion (P=0.336 and 0.173, respectively). Furthermore, serial arteriography was used to predict a good histologic response with an accuracy of 73.1% and a sensitivity of 100%. There were sporadic cases with the telangiectatic subtype, which did not respond very well to IV chemotherapy, but later, the tumor obviously shrank after IA infusion of cisplatin. Our study also showed that the rates of the complication of skin and muscle necrosis were not so low as reported. Conclusion: We did not observe any survival advantage of chemotherapy using IA infusion in osteosarcoma of the extremities. Arteriography for TNV can be used to predict the tumor histologic response. Malposition of the catheter might severely increase the complication of skin or muscle necrosis.

Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy

Superior mesenteric artery embolism associated with Cisplatin-induced aortic thrombosis

Cisplatin-induced Cardiotoxicity with Midrange Ejection Fraction A Case Report and Review of the Literature

Impact of Sodium Thiosulfate on Prevention of Nephrotoxicities in HIPEC: An Ancillary Evaluation of Cisplatin-Induced Toxicities in Ovarian Cancer

Pharmacokinetics of Cisplatin in the Systemic versus Hyperthermic Intrathoracic or Intraperitoneal Chemotherapy

Efficacy of Cisplatin–CXCR4 Antagonist Combination Therapy in Oral Cancer

Cisplatin-induced Cardiotoxicity with Midrange Ejection Fraction

A case of aortitis during cisplatin-based chemotherapy for cervical cancer

PKPD Modeling and Dosing Considerations in Advanced Ovarian Cancer Patients Treated with Cisplatin-Based Intraoperative Intraperitoneal Chemotherapy

Cmar_a_214604 7183..7195

Eliminating the need for preoperative intravenous hyperhydration: Sodium thiosulfate as nephrotoxicity prevention in HIPEC-treated patients – A retrospective analysis

Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study

A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis

An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures

Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy

Gain and Loss from Transcatheter Intra-Arterial Limb Infusion of Cisplatin for Extremity Osteosarcoma: a Retrospective Study of 99 Cases in the Past Six Years.

Clinical insights into cisplatin-induced arrhythmia in a patient with locally advanced non-small cell lung cancer: a case report

Nephrotoxicity and Long-Term Survival Investigations for Patients with Peritoneal Carcinomatosis Using Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Retrospective Cohort Study.

Treatment of acute ST-segment elevation myocardial infarction patients with high thrombus burden and failure primary percutaneous coronary intervention

Reduction of Cisplatin-Induced Ototoxicity without Compromising Its Antitumor Activity

Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin